Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 6/20 | 0.62 |
| ▸ | SLC9A2 | Q9UBY0 | 3/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.61 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.47 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6262880 | 0.92 | SLC9A1 (0.74) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL7686352 | 0.91 | SLC9A1 (0.74) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL4456220 | 0.85 | SLC9A1 (0.86) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL6315017 | 0.84 | SLC9A1 (0.87) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL4456213 | 0.84 | SLC9A1 (0.61) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL6315010 | 0.83 | SLC9A1 (0.61) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6312663 | 0.81 | SLC9A1 (0.71) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6669854 | 0.81 | SLC9A1 (0.72) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6320763 | 0.80 | SLC9A1 (0.60) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6588864 | 0.79 | SLC9A1 (0.68) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | SLC9A1 5/4885SLC9A2 12/4885OPRM1 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.